focus -WSS

focus

author：focus 2025-10-01 17:34:21 - browse：13565

Smartphone & medicine illustration — Alex Hogan/STAT

Pear Therapeutics may be gone, but one of its most important deals is still driving critical conversations about how medical apps can find a foothold in the slow-moving health care system.

In recent months, representatives of the Massachusetts state Medicaid program, MassHealth, have been presenting data suggesting reSET and reSET-O, Pear’s prescription apps that treat substance use disorder and opioid use disorder, saved the state money over a one-year period from 2021 to 2022. The data, which take into account health care utilization before and after people used the apps, have been presented to policymakers considering how to cover novel digital health products and shown to lawmakers considering federal legislation that would require Medicare coverage for prescription apps.

Pear, which filed for bankruptcy earlier this year, was one of the leading companies marketing prescription digital therapeutics, or Food and Drug Administration-cleared apps designed to treat disease. Pear’s reSET was the first such app cleared by the FDA in 2017.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare drug price negotiation’s day in court

knowledge

WSS

Sanofi seeks simpler, safer CRISPR sickle cell cure

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Medicare has a new plan to address drug shortages

FDA drug safety: Singulair case shows systemic surveillance flaws

Google and Epic fight stronger regulation of AI in health care

Listen: Wegovy in the brain & pivotal Alzheimer's data

knowledge

focus

explore

Medical leaders decry Supreme Court decision on affirmative action

SAMSHA loosens regulations on methadone treatment centers

ChatGPT in medicine: STAT answers readers' burning questions

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Psychedelics group wrestles with new pharma identity

Google and Epic fight stronger regulation of AI in health care

As demand for Covid shots wanes, Moderna seeks its next success

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Novo Nordisk to expand supply of Wegovy for U.S. patients

Cognito secures funding to test medical device for Alzheimer's

Woodcock on FDA’s accelerated approval and her next chapter

Juul spent big to court Black leaders to promote its e

Sanders adds drug shortage policies to pandemic preparedness bill

focus

focus

knowledge

focus